Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$1.76B |
| 2 |
Tesla
TSLA
|
$1.37B |
| 3 |
Amazon
AMZN
|
$623M |
| 4 |
AbbVie
ABBV
|
$398M |
| 5 |
Qualcomm
QCOM
|
$394M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
$603M |
| 3 |
Micron Technology
MU
|
$366M |
| 4 |
Meta Platforms (Facebook)
META
|
$365M |
| 5 |
UnitedHealth
UNH
|
$353M |
Sector Composition
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.91% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.47% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$96B
| $3.86B | 2.97% | 60,210,661 +27,452,891 | +84% | +$1.76B |
|
|
2
Tesla
TSLA
$1.08T
| $1.65B | 1.27% | 3,938,142 +3,267,141 | +487% | +$1.37B |
|
3
VeriSign
VRSN
$25.5B
| $1.59B | 1.22% | 8,270,690 -11,886 | -0.1% | -$2.29M |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $1.55B | 1.19% | 7,076,582 +1,277,465 | +22% | +$280M |
|
5
Novo Nordisk
NVO
$251B
| $1.52B | 1.17% | 26,217,026 +1,430,310 | +6% | +$82.8M |
|
6
Chipotle Mexican Grill
CMG
$56.5B
| $1.48B | 1.13% | 1,763,542 -150,900 | -8% | -$126M |
|
7
Biogen
BIIB
$19.4B
| $1.36B | 1.04% | 4,569,906 +348,700 | +8% | +$103M |
|
8
Palo Alto Networks
PANW
$127B
| $1.31B | 1.01% | 5,662,451 -185,699 | -3% | -$42.9M |
|
9
Gilead Sciences
GILD
$140B
| $1.1B | 0.85% | 16,962,944 +2,228,686 | +15% | +$145M |
|
10
Humana
HUM
$36.5B
| $1.08B | 0.83% | 2,951,242 -5,076 | -0.2% | -$1.86M |
|
11
Walmart
WMT
$774B
| $1.06B | 0.82% | 8,926,837 +1,614,100 | +22% | +$192M |
|
|
12
AbbVie
ABBV
$372B
| $1.04B | 0.8% | 11,796,744 +4,490,046 | +61% | +$398M |
|
|
AGN
13
DELISTED
Allergan plc
AGN
| $960M | 0.74% | 5,019,812 +1,345,644 | +37% | +$257M |
|
14
Petrobras
PBR
$79.9B
| $904M | 0.69% | 56,695,930 +13,270,530 | +31% | +$212M |
|
15
GSK
GSK
$79.9B
| $894M | 0.69% | 19,027,599 +1,475,900 | +8% | +$69.4M |
|
16
GE Aerospace
GE
$292B
| $844M | 0.65% | 75,624,926 +15,404,966 | +26% | +$172M |
|
17
Amgen
AMGN
$155B
| $762M | 0.59% | 3,159,538 -498,548 | -14% | -$120M |
|
18
Atlassian
TEAM
$46.6B
| $732M | 0.56% | 6,081,924 +630,125 | +12% | +$75.8M |
|
19
Align Technology
ALGN
$10.3B
| $729M | 0.56% | 2,610,848 +394,948 | +18% | +$110M |
|
20
Monster Beverage
MNST
$60.9B
| $728M | 0.56% | 11,452,315 +1,934,311 | +20% | +$123M |
|
21
Target
TGT
$43.6B
| $727M | 0.56% | 5,671,968 +1,517,068 | +37% | +$195M |
|
22
Hershey
HSY
$37.3B
| $660M | 0.51% | 4,491,062 -337,853 | -7% | -$49.7M |
|
23
Vodafone
VOD
$28.8B
| $657M | 0.5% | 33,972,220 +4,649,003 | +16% | +$89.9M |
|
|
24
Meta Platforms (Facebook)
META
$1.86T
| $649M | 0.5% | 3,159,939 -1,780,294 | -36% | -$365M |
|
25
BP
BP
$90.8B
| $645M | 0.5% | 17,090,262 -708,400 | -4% | -$26.7M |
|